Meta-analysis of Clinical Efficacy of Metformin Combined with Chemotherapy in the Treatment of Ovarian Cancer
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v3i1.709
Abstract
Objective — To systematically evaluate the clinical efficacy of metformin combined with chemotherapy in the treatment of patients with ovarian cancer. Methods — Methods: Search Pubmed, Embase, Web of science, Cochrane Library database, and screen the literature of randomized controlled trials and cohort studies of metformin combined with chemotherapy in the treatment of ovarian cancer, and use Revman5.2 software to conduct meta-analysis to compare metformin combined with chemotherapy (experimental Group) or chemotherapy alone (control group) for the treatment of ovarian cancer. Results — A total of 389 articles were retrieved, and 4 cohort studies and 2 randomized controlled trials were screened and included, involving 2010 patients with ovarian cancer. Compared with the control group, the overall survival rate of metformin combined with chemotherapy in patients with ovarian cancer (HR=0.55, 95% confidence interval 0.34-0.89, P=0.01, I2=36%), progression-free survival rate (HR=0.43, The 95% confidence interval 0.20-0.96, P=0.04, I2=42%) and disease-free survival rate (HR=0.24, 95% confidence interval 0.11-0.50, P=0.0001) were significantly better than the control group. Conclusion — Metformin combined with chemotherapy can significantly improve the therapeutic effect of patients with ovarian cancer.
Keywords
metformin, ovarian cancer, chemotherapy, survival rate
Funding
The National Natural Science Foundation of China (NSFC)(81560038)
Full Text
PDF - Viewed/Downloaded: 3 TimesIndexation
Download Index RecordReferences
[2]Torre LA, Bray V, Siegel RL, et al. Global cancer statistics[J]. CA Cancer J Clin, 2015; 65(3): 87-108.
[3]Liang WF, Wang LJ, Li H, et al. The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease [J]. J Cancer, 2021; 12(3): 946-953.
[4]Shen Xiameng, Lv Weiguo. Study on the role of exosomes in chemotherapy resistance of ovarian cancer patients [J]. Journal of Zhejiang University, 2019; 48(1): 116-120.
[5]Raja FA, Counsell N, Colombo N, et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data[J]. Ann Oncol, 2013; 24(12): 3028-34.
[6]Block KI, Gyllenhaal C, Lowe L, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment[J]. Semin Cancer Biol, 2015; 35 Suppl(Suppl): S276-s304.
[7]Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin[J]. Gastroenterology, 2001; 120(5): 1263-70.
[8]Kobayashi Y, Banno K, Kunitomi H, et al. Current state and outlook for drug repositioning anticipated in the field of ovarian cancer[J]. Journal of Gynecologic Oncology, 2019; 30(1): 1-13.
[9]Higgins JP, Thompson SG.Quantifying heterogeneity in a meta-analysis[J]. Stat Med, 2002; 21(11): 1539-58.
[10]Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test[J]. Bmj, 1997; 315(7109): 629-34.
[11]Wen KC, Sung PL, Wu ATH, et al. Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer[J]. J Ovarian Res, 2020; 13(1): 95.
[12]Wang SB, Lei KJ, Liu JP, al. Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer: A retrospective study[J]. Medicine (Baltimore), 2017; 96(29): e7605.
[13]Kumar SA, Meuter, Thapa P, et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study[J]. Cancer, 2013; 119(3): 555-62.
[14]14 Romero IL, McCormick A, McEwen KA, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity[J]. Obstet Gynecol, 2012; 119(1): 61-7.
[15]Hamedi B, Khalili A, Roozmeh S, et al. Combination of Metformin and Chemotherapy Decreases the Recurrence Rates of Epithelial Ovarian Cancers: A Randomized Clinical Trial[J]. International Journal of Cancer Management, 2018; 11(7): 1-7.
[16]Zheng Y, Zhu J, Zhang H, et al. Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial[J]. Cancer Chemother Pharmacol, 2019; 84(6): 1349-1357.
[17]Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis[J]. Diabetes Care, 2011; 34(10): 2323-8.
[18]Zhang ZJ, Zheng ZJ, Shi R, et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2012; 97(7): 2347-53.
[19]Zhang ZJ, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis[J]. Am J Epidemiol, 2014; 180(1): 11-4.
[20]Zhang ZJ. Metformin and Reduced Risk of Cancer in the Hong Kong Diabetes Registry: Real Effect or Immortal Time Bias?[J]. J Gen Intern Med, 2019; 34(7): 1154-1157.
[21]Zhang F, Chen H, Du J, et al. Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway [J]. Med Sci Monit, 2018; 24: 6093-6101.
[22]Zheng Y, Zhu J, Zhang H, et al. Metformin inhibits ovarian cancer growth and migration in vitro and in vivo by enhancing cisplatin cytotoxicity[J]. Am J Transl Res, 2018; 10(10): 3086-3098.
Copyright © 2022 Caiyu Li, Liming Tan, Weihua Zhou
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License